Molecular Dimensions of Gastric Cancer: Translational and Clinical Perspectives

키워드

참고문헌 (87)

1. Ferlay J, "Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012", Int J Cancer, 136, pp.E359~E386 (2015)
2. 정규원, "Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2012", Cancer Research and Treatment, 47(2), pp.127~141 (2015), 대한암학회[DOI]
3. 정규원, "Prediction of Cancer Incidence and Mortality in Korea, 2015", Cancer Research and Treatment, 47(2), pp.142~148 (2015), 대한암학회[DOI]
4. 이경숙, "Gastric Cancer Screening in Korea: Report on the National Cancer Screening Program in 2008", Cancer Research and Treatment, 43(2), pp.83~88 (2011), 대한암학회
5. 서민아, "Trends in Cancer Screening Rates among Korean Men and Women: Results from the Korean National Cancer Screening Survey, 2004-2012", Cancer Research and Treatment, 45(2), pp.86~94 (2013), 대한암학회
6. Ajani JA, "Gastric cancer, version 2.2013: featured updates to the NCCN Guidelines", Natl Compr Canc Netw, 11, pp.531~546 (2013)
7. Waddell T, "Gastric cancer: ESMO-ESSOESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up", Ann Oncol, 24(Suppl 6), pp.57~63 (2013)
8. Japanese Gastric Cancer Association, "Japanese gastric cancer treatment guidelines 2010 (ver. 3)", Gastric Cancer, 14, pp.113~123 (2011)
9. Songun I, "Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial", Lancet Oncol, 11, pp.439~449 (2010)
10. Wu CW, "Nodal dissection for patients with gastric cancer: a randomised controlled trial", Lancet Oncol, 7, pp.309~315 (2006)
11. Bang YJ, "Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial", Lancet, 379, pp.315~321 (2012)
12. Noh SH, "Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial", Lancet Oncol, 15, pp.1389~1396 (2014)
13. Sakuramoto S, "Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine", N Engl J Med, 357, pp.1810~1820 (2007)
14. Sasako M, "Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer", J Clin Oncol, 29, pp.4387~4393 (2011)
15. Ohtsu A, "Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study", J Clin Oncol, 29, pp.3968~3976 (2011)
16. Bang YJ, "Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial", Lancet, 376, pp.687~697 (2010)
17. Bosman FT, "WHO classification of tumours of the digestive system" (2010), IARC Press
18. Lauren P, "The Two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma: an attempt at a histoclinical classification", Acta Pathol Microbiol Scand, 64, pp.31~49 (1965)
19. 최윤영, "Evolution of Gastric Cancer Treatment: From the Golden Age of Surgery to an Era of Precision Medicine", Yonsei Medical Journal, 56(5), pp.1177~1185 (2015), 연세대학교의과대학[DOI]
20. Cancer Genome Atlas Research Network, "Comprehensive molecular characterization of gastric adenocarcinoma", Nature, 513, pp.202~209 (2014)
21. Muro K, "A phase 1B study of pembrolizumab (Pembro; MK-3475) in patients (pts) with advanced gastric cancer", Ann Oncol, 25(Suppl 4), pp.LBA15~ (2014)
22. Mueller A, "Selective PI3K inhibition by BKM120 and BEZ235 alone or in combination with chemotherapy in wild-type and mutated human gastrointestinal cancer cell lines", Cancer Chemother Pharmacol, 69, pp.1601~1615 (2012)
23. Le DT, "PD-1 blockade in tumors with mismatch-repair deficiency", N Engl J Med, 372, pp.2509~2520 (2015)
24. Huntsman DG, "Early gastric cancer in young, asymptomatic carriers of germ-line E-cadherin mutations", N Engl J Med, 344, pp.1904~1909 (2001)
25. Lordick F, "Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial", Lancet Oncol, 14, pp.490~499 (2013)
26. Waddell T, "Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial", Lancet Oncol, 14, pp.481~489 (2013)
27. Satoh T, "Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN: a randomized, phase III study", J Clin Oncol, 32, pp.2039~2049 (2014)
28. Lennerz JK, "MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib", J Clin Oncol, 29, pp.4803~4810 (2011)
29. Iveson T, "Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a doubleblind, randomised phase 2 study", Lancet Oncol, 15, pp.1007~1018 (2014)
30. Doshi S, "Rilotumumab exposure-response relationship in patients with advanced or metastatic gastric cancer", Clin Cancer Res, 21, pp.2453~2461 (2015)
31. "Amgen announces termination of all amgen-sponsored clinical studies of rilotumumab in advanced gastric cancer" (2014)[URL]
32. Van Cutsem E, "Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial", J Clin Oncol, 30, pp.2119~2127 (2012)
33. Fuchs CS, "Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial", Lancet, 383, pp.31~39 (2014)
34. Wilke H, "Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial", Lancet Onc, 15, pp.1224~1235 (2014)
35. Murphy G, "Meta-analysis shows that prevalence of Epstein-Barr virus-positive gastric cancer differs based on sex and anatomic location", Gastroenterology, 137, pp.824~833 (2009)
36. Kaneda A, "Epstein-Barr virus infection as an epigenetic driver of tumorigenesis", Cancer Res, 72, pp.3445~3450 (2012)
37. Tan P, "Genetics and molecular pathogenesis of gastric adenocarcinoma", Gastroenterology, 149, pp.1153~1162 (2015)
38. Grogg KL, "Lymphocyte-rich gastric cancer: associations with Epstein-Barr virus, microsatellite instability, histology, and survival", Mod Pathol, 16, pp.641~651 (2003)
39. Wang K, "Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer", Nat Genet, 43, pp.1219~1223 (2011)
40. Bitler BG, "Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers", Med, 21, pp.231~238 (2015)
41. An JY, "Microsatellite instability in sporadic gastric cancer: its prognostic role and guidance for 5-FU based chemotherapy after R0 resection", Int J Cancer, 131, pp.505~511 (2012)
42. Lee HS, "Distinct clinical features and outcomes of gastric cancers with microsatellite instability", Mod Pathol, 15, pp.632~640 (2002)
43. Choi YY, "Is microsatellite instability a prognostic marker in gastric cancer? A systematic review with meta-analysis", J Surg Oncol, 110, pp.129~135 (2014)
44. Cristescu R, "Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes", Nat Med, 21, pp.449~456 (2015)
45. Kim SY, "The benefit of microsatellite instability is attenuated by chemotherapy in stage II and stage III gastric cancer: results from a large cohort with subgroup analyses", Int J Cancer, 137, pp.819~825 (2015)
46. Ribic CM, "Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer", N Engl J Med, 349, pp.247~257 (2003)
47. Sargent DJ, "Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer", J Clin Oncol, 28, pp.3219~3226 (2010)
48. Snyder A, "Genetic basis for clinical response to CTLA-4 blockade in melanoma", N Engl J Med, 371, pp.2189~2199 (2014)
49. Rizvi NA, "Cancer immunology: mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer", Science, 348, pp.124~128 (2015)
50. "Clinical Practice Guidelines in Oncology (NCCN guidelines): colon cancer, version 2.2015" (2014)[URL]
51. Suraweera N, "Evaluation of tumor microsatellite instability using five quasimonomorphic mononucleotide repeats and pentaplex PCR", Gastroenterology, 123, pp.1804~1811 (2002)
52. Buhard O, "Multipopulation analysis of polymorphisms in five mononucleotide repeats used to determine the microsatellite instability status of human tumors", J Clin Oncol, 24, pp.241~251 (2006)
53. Corso G, "Somatic mutations and deletions of the E-cadherin gene predict poor survival of patients with gastric cancer", J Clin Oncol, 31, pp.868~875 (2013)
54. Wang K, "Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer", Nat Genet, 46, pp.573~582 (2014)
55. Kakiuchi M, "Recurrent gain-of-function mutations of RHOA in diffuse-type gastric carcinoma", Nat Genet, 46, pp.583~587 (2014)
56. Ridley AJ, "Cell migration : integrating signals from front to back", Science, 302, pp.1704~1709 (2003)
57. Thumkeo D, "Physiological roles of Rho and Rho effectors in mammals", Eur J Cell Biol, 92, pp.303~315 (2013)
58. Yao F, "Recurrent fusion genes in gastric cancer: CLDN18-ARHGAP26 induces loss of epithelial integrity", Cell Rep, 12, pp.272~285 (2015)
59. Hanazono K, "Distribution of p53 mutations in esophageal and gastric carcinomas and the relationship with p53 expression", Oncol Rep, 15, pp.821~824 (2006)
60. Lei Z, "Identification of molecular subtypes of gastric cancer with different responses to PI3-kinase inhibitors and 5-fluorouracil", Gastroenterology, 145, pp.554~565 (2013)
61. Grabsch HI, "Gastric cancer pathology and underlying molecular mechanisms", Dig Surg, 30, pp.150~158 (2013)
62. Jimeno A, "Blockade of epidermal growth factor receptor(EGFR)activity", Crit Rev Oncol Hematol, 53, pp.179~192 (2005)
63. Terashima M, "Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II", III gastric cancer, 2012, pp.18, 5992~6000
64. "Office of Medical Products and Tobacco" (2010)[URL]
65. Fukuoka M, "Biomarker analyses and final overall survival results from a phase III, randomized, openlabel, first-line study of gefitinib versus carboplatin", paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS), 2011, pp.29, 2866~2874
66. Lee J, "Towards the goal of personalized medicine in gastric cancer: time to move beyond HER2 inhibition. Part II: Targeting gene mutations and gene amplifications and the angiogenesis pathway", Discov Med, 16, pp.7~14 (2013)
67. van Grieken NC, "KRAS and BRAF mutations are rare and related to DNA mismatch repair deficiency in gastric cancer from the East and the West: results from a large international multicentre study", Br J Cancer, 108, pp.1495~1501 (2013)
68. Cepero V, "MET and KRAS gene amplification mediates acquired resistance to MET tyrosine kinase inhibitors", Cancer Res, 70, pp.7580~7590 (2010)
69. Janne PA, "Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study", Lancet Oncol, 14, pp.38~47 (2013)
70. Davies H, "Mutations of the BRAF gene in human cancer", Nature, 417, pp.949~954 (2002)
71. Puzanov I, "Long-term outcome in BRAF(V600E) melanoma patients treated with vemurafenib: patterns of disease progression and clinical management of limited progression", Eur J Cancer, 51, pp.1435~1443 (2015)
72. Lee SH, "BRAF and KRAS mutations in stomach cancer", Oncogene, 22, pp.6942~6945 (2003)
73. Hurwitz H, "Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer", N Engl J Med, 350, pp.2335~2342 (2004)
74. Sandler A, "Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer", N Engl J Med, 355, pp.2542~2550 (2006)
75. Shah MA, "Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma", J Clin Oncol, 29, pp.868~874 (2011)
76. Shah MA, "Gastrointestinal cancer: targeted therapies in gastric cancer-the dawn of a new era", Nat Rev Clin Oncol, 11, pp.10~11 (2014)
77. Subramaniam D, "Cancer stem cells: a novel paradigm for cancer prevention and treatment", Mini Rev Med Chem, 10, pp.359~371 (2010)
78. Tan DS, "Anti-cancer drug resistance: understanding the mechanisms through the use of integrative genomics and functional RNA interference", Eur J Cancer, 46, pp.2166~2177 (2010)
79. Peinado H, "Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype?", Nat Rev Cancer, 7, pp.415~428 (2007)
80. Voutsadakis IA, "The ubiquitin-proteasome system and signal transduction pathways regulating epithelial mesenchymal transition of cancer", J Biomed Sci, 19, pp.67~ (2012)
81. Bierie B, "Tumour microenvironment : TGFbeta : the molecular Jekyll and Hyde of cancer", Nat Rev Cancer, 6, pp.506~520 (2006)
82. Watabe T, "Roles of TGF-beta family signaling in stem cell renewal and differentiation", Cell Res, 19, pp.103~115 (2009)
83. Zhou J, "Activation of the PTEN", mTOR, Proc Natl Acad Sci U S A, pp.2007, 104[DOI]
84. Hirsch HA, "Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission", Cancer Res, 69, pp.7507~7511 (2009)
85. Choong-kun Lee, "Cumulative Metformin Use and Its Impact on Survival in Gastric Cancer Patients After Gastrectomy", Annals of Surgery, 263(1), pp.96~102 (2016), Ovid Technologies (Wolters Kluwer Health)[DOI]
86. Takaishi S, "Identification of gastric cancer stem cells using the cell surface marker CD44", Stem Cells, 27, pp.1006~1020 (2009)
87. Wadhwa R, "Gastric cancermolecular and clinical dimensions", Nat Rev Clin Oncol, 10, pp.643~655 (2013)

관련 논문AI추천